Company News: Page (1) of 1 - 07/01/14 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Bristol-Myers Squibb Company - Product Pipeline Review - 2014

  (July 01, 2014)

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bristol-Myers Squibb Company - Product Pipeline Review - 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/bristol_myers_squibb_company_product_pipeline_review_2013.html

Bristol-Myers Squibb Company - Product Pipeline Review - 2014


Summary

Global Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bristol-Myers Squibb Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bristol-Myers Squibb Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Bristol-Myers Squibb Company's pipeline products

Reasons to buy

- Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bristol-Myers Squibb Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bristol-Myers Squibb Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents

Bristol-Myers Squibb Company Snapshot 7
Bristol-Myers Squibb Company Overview 7
Key Information 7
Key Facts 7
Bristol-Myers Squibb Company - Research and Development Overview 8
Key Therapeutic Areas 8
Bristol-Myers Squibb Company - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Combination Treatment Modalities 19
Pipeline Products - Partnered Products 20
Pipeline Products - Out-Licensed Products 23
Bristol-Myers Squibb Company - Pipeline Products Glance 27
Bristol-Myers Squibb Company - Late Stage Pipeline Products 27
Bristol-Myers Squibb Company - Clinical Stage Pipeline Products 29
Bristol-Myers Squibb Company - Early Stage Pipeline Products 35
Bristol-Myers Squibb Company - Drug Profiles 39
(atazanavir sulfate + cobicistat) 39
apixaban 41
asunaprevir 43
asunaprevir + daclatasvir 45
daclatasvir 47
(daclatasvir + asunaprevir + beclabuvir) 49
abatacept 50
beclabuvir 53
ipilimumab 55
ixabepilone 58
nivolumab 60
peginterferon lambda-1a 64
BMS-663068 66
BMS-690514 68
BMS-754807 70
BMS-813160 72
BMS-817399 73
BMS-833923 74
BMS-919373 76
BMS-954561 77
BMS-955176 78
BMS-986020 79
BMS-986036 80
censavudine 81
clazakizumab 82
dasatinib 84
eldelumab 87
lirilumab 89
pegdinetanib 90
rimegepant 92
Small Molecule for HIV 94
Triple Reuptake Inhibitors 95
BMS-911543 96
Anti-CD40 Antibody Program 98
Antibody Targeting CD40 Ligand for Immunology 99
BMS-241027 100
BMS-262084 101
BMS-394136 102
BMS-777607 103
BMS-906024 104
BMS-933043 105
BMS-936559 106
BMS-962476 107
BMS-981164 108
BMS-986016 109
BMS-986046 110
BMS-986089 111
BMS-986115 112
denenicokin 113
Iso-fludelone 115
MDX-1203 117
MDX-1303 118
MDX-1401 120
MDX-1411 121
Monoclonal Antibody to Antagonize CD28 for Immunology 122
Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 123
ulocuplumab 124
urelumab 125
XL-652 127
BMS-817378 129
Acrylamide (S)-6 130
ALB-109780 131
ARX-720 Relaxin 132
BMS-299897 133
BMS-457 134
BMS-585248 135
BMS-593214 136
BMS-795311 137
BMS-816106 138
BMS-871 139
Drug For Cancer 140
EGFR/IGFR Tandem Adnectin 141
EHT/AGN-0002 142
IPN-002 143
IPN-007 144
noscapine 145
Small Molecule to Inhibit Factor XIa for Thrombosis 146
Small Molecule to Inhibit P2Y1 for Thrombosis 147
Small Molecules to Inhibit ROR for Inflammation 148
Bicyclic Triazoles 149
Bispecific Antibody for Non-Hodkins Lymphoma 150
Bruton's Tyrosine Kinase Inhibitor 151
Drug For Metabolic Disorders 152
Monoclonal Antibodies for Cancer 153
Monoclonal Antibodies Targeting Complement System 154
Monoclonal Antibodies Targeting Tau Protein 155
Monoclonal Antibodies to Target CTLA-4 for Cancer 156
Next Generation Antibody Drug Conjugates for Oncology 157
Proteins for Immunology and Cancer 158
Small Molecules for Undisclosed Indication 159
Bristol-Myers Squibb Company - Pipeline Analysis 160
Bristol-Myers Squibb Company - Pipeline Products by Target 160
Bristol-Myers Squibb Company - Pipeline Products by Route of Administration 165
Bristol-Myers Squibb Company - Pipeline Products by Molecule Type 166
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action 168
Bristol-Myers Squibb Company - Recent Pipeline Updates 173
Bristol-Myers Squibb Company - Dormant Projects 207
Bristol-Myers Squibb Company - Discontinued Pipeline Products 216
Discontinued Pipeline Product Profiles 217
Bristol-Myers Squibb Company - Company Statement 222
Bristol-Myers Squibb Company - Locations And Subsidiaries 225
Head Office 225
Other Locations & Subsidiaries 225
Bristol-Myers Squibb Company - Key Manufacturing Facilities 230
Appendix 231
Methodology 231
Coverage 231
Secondary Research 231
Primary Research 231
Expert Panel Validation 231
Contact Us 232
Disclaimer 232

List of Tables

Bristol-Myers Squibb Company, Key Information 13
Bristol-Myers Squibb Company, Key Facts 13
Bristol-Myers Squibb Company - Pipeline by Indication, 2014 16
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2014 23
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2014 24
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2014 25
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2014 26
Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2014 27
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2014 29
Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2014 30
Bristol-Myers Squibb Company - Pre-Registration, 2014 33
Bristol-Myers Squibb Company - Phase III, 2014 34
Bristol-Myers Squibb Company - Phase II, 2014 35
Bristol-Myers Squibb Company - Phase I, 2014 38
Bristol-Myers Squibb Company - IND/CTA Filed, 2014 41
Bristol-Myers Squibb Company - Preclinical, 2014 42
Bristol-Myers Squibb Company - Discovery, 2014 44
Bristol-Myers Squibb Company - Pipeline by Target, 2014 167
Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2014 171
Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2014 173
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2014 175
Bristol-Myers Squibb Company - Recent Pipeline Updates, 2014 179
Bristol-Myers Squibb Company - Dormant Developmental Projects,2014 213
Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2014 222
Bristol-Myers Squibb Company, Other Locations 231
Bristol-Myers Squibb Company, Subsidiaries 232
Bristol-Myers Squibb Company, Key Manufacturing Facilities 236

List of Figures

Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2014 16
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2014 23
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2014 24
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2014 25
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2014 26
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2014 29
Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2014 166
Bristol-Myers Squibb Company - Pipeline by Top 10 Route of Administration, 2014 171
Bristol-Myers Squibb Company - Pipeline by Top 10 Molecule Type, 2014 172
Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2014 174

Read the full report:
Bristol-Myers Squibb Company - Product Pipeline Review - 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/bristol_myers_squibb_company_product_pipeline_review_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Pro AV, Post/Production, Presentors, Business, Standards/Initiatives, Business Issues, Presentation, Mergers & Acquistion, Medicine, Disease, Sexual, Cancer, Surgery, Medication, Science, Medical, Cancer, Business, Other,

HOT THREADS on DMN Forums

@ Copyright, 2014 Digital Media Online, All Rights Reserved